NSE / BSEHealthcare
βΉ2222.05-14.25-0.64%
P/E55.1Mkt CapβΉ8.75 K CrEV/EBITDA55.0
Corona Remedies Limited
P/E55.1Mkt CapβΉ8.75 K CrEV/EBITDA55.0
Company Profile
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
Valuation
Market Cap
βΉ0.00
β
Current Price
βΉ0
βas of 15 Sept 2026
P/E Ratio
0.0x
β
P/B Ratio
β
β
EV / EBITDA
0.0x
β
EV / Sales
0.0x
β
52W High
βΉ0
β
52W Low
βΉ0
β
Shares Out
0.00 Cr
β
Profitability
Operating Margin
0.0%
β
Net Profit Margin
0.0%
β
EBITDA Margin
0.0%
β
Returns
ROE
0.0%
β
ROCE
0.0%
β
ROIC %
β
β
ROA
0.0%
β
Dividend Payout
0.0%
β
Solvency
Current Ratio
0.0x
β
Debt / Equity
0.0x
β
Debt / Assets
0.0x
β
CFO / Net Profit
0.0x
β
Interest Coverage
0.0x
β
AI Summary
Indian StockStrengths1
- Healthy return on equity of 18.8%
Concerns1
- Negative free cash flow (βΉ11 Cr)
Rule-based from financial data. Not advice.
Price Historyβ² 54.61% over 1Y
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
RevenueβΉ1.20 K Crβ² 17.9%
EBITDA Growthβ
Net ProfitβΉ149.00 Crβ² 65.6%
Cash from Ops (CFO)β
Free Cash Flow (FCF)ββΌ 100.0%
Revenue CAGR 5Y11.0%
EBITDA CAGR 5Y10.9%
Net Profit CAGR 5Y8.8%
NP Growth 1Y65.6%
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 7 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.20 K Cr | β | βΉ149.00 Cr | β | β | 24.6% | 17.9% | 65.6% |
| Mar 2024 | βΉ1.01 K Cr | β | βΉ90.00 Cr | β | β | 18.8% | 14.7% | 5.9% |
| Mar 2023 | βΉ884.00 Cr | β | βΉ85.00 Cr | β | β | 20.8% | 43.3% | β |
| Mar 2022 | βΉ617.00 Cr | β | βΉ0.00 | β | β | 0.0% | 7.1% | -100.0% |
| Mar 2021 | βΉ576.00 Cr | β | βΉ70.00 Cr | β | β | 20.7% | -4.2% | 18.6% |
| Mar 2020 | βΉ601.00 Cr | β | βΉ59.00 Cr | β | β | 22.0% | 18.1% | 68.6% |
| Mar 2019 | βΉ509.00 Cr | β | βΉ35.00 Cr | β | β | 16.7% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Free plan Β· showing 1 year of data.Upgrade
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2025 |
|---|---|
| Revenue / Net Sales | 1,196 |
| Total Expenses | 956 |
| EBIT / Operating Profit | 241 |
| OPM % | 20% |
| Other Income | 5 |
| Finance Costs | 11 |
| Depreciation & Amortisation | 37 |
| Profit Before Tax | 198 |
| Tax % | 25% |
| Net Profit / PAT | 149 |
| EPS (βΉ) | 24.37 |
| Dividend Payout % | 30% |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Corona Remedies Limitedthis co. | βΉ8.75 K Cr | βΉ1.20 K Cr | 55.10 | 0.00 | 54.96 | 17.9% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |